Pricing for orphan drugs: Will the market bear what society cannot?

JAMA

Volumn 310, Issue 13, 2013, Pages 1343-1344

  O'Sullivan, Brian P ^a   Orenstein, David M ^b   Milla, Carlos E ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; IDURONATE 2 SULFATASE; IMIGLUCERASE; IVACAFTOR; ORPHAN DRUG; TREPROSTINIL;

COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DOCTOR PATIENT RELATION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; GAUCHER DISEASE; HEALTH CARE NEED; HUMAN; HUNTER SYNDROME; MEDICAL ETHICS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SHORT SURVEY;

EID: 84884931356     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.278129     Document Type: Short Survey

References (10)

1. Cystic Fibrosis Foundation. 2011 CFF Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation Patient Registry; 2012.
2. Rowe SM, Borowitz DS, Burns JL, et al. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax. 2012;67(10):882-890.
3. Cystic Fibrosis Services Pharmacy Products and Prices. Cystic Fibrosis Services website. www.cfservicespharmacy.com/ProductsandPrices/. 2013. Accessed June 22, 2013.
4. Ledford H. Charities seek cut of drug royalties. Nature. 2011;475(7356):275-276.
5. Barrett PM, Alagely A, Topol EJ. Cystic fibrosis in an era of genomically guided therapy. Hum Mol Genet. 2012;21(R1):R66-R71.
6. Banner A, Nead C,Wyke A. The corporate reputation of pharma - the patient perspective. PatientView Q. 2013:1-51.
7. Centers for Medicare & Medicaid Services (CMS). National Health Expenditures 2011 Highlights. CMS website. www.cms.gov/Research-Statistics-Data- and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/ highlights.pdf. 2012. Accessed June 22, 2013.
8. Kantarjian H. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML Experts [published online April 23, 2013]. Blood. doi:10.1182/blood-2013-03-490003.
9. Bush A, Simmonds NJ. Hot off the breath: "I've a cost for" - the 64-million-dollar question. Thorax. 2012;67(5):382-384.
10. NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for PeopleWith a Specific Genetic Mutation (G551D). Vertex website. http://investors.vrtx.com/releasedetail.cfm? ReleaseID=727822. December 19, 2012. Accessed June 23, 2013.